November 7, 2016 / 6:17 AM / 10 months ago

BRIEF-Mologen 9-mth EBIT loss widens to 14.3 mln euros

Nov 7 (Reuters) - Mologen AG :

* Outlook unchanged for full-year 2016

* Capital increase and convertible bond with gross proceeds of presumably 16.1 million euros ($17.82 million)

* First anti-tumor data of TLR9 agonist Enandim in a murine model

* Advancement of four clinical studies with lead product lefitolimod (MGN1703)

* 9Mth EBIT at -14.3 million euros was below previous year's value of -13.3 million euros as a result of rise on operating expenses

* Capital increase presumably secures financing up to Q4 of 2017

* As of 30 September 2016, Mologen AG's cash and cash equivalents totaled 10.2 million euros (Dec. 31, 2015: 24.6 million euros) Source text for Eikon: Further company coverage: ($1 = 0.9035 euros) (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below